Published in N Engl J Med on September 07, 2006
Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell (2008) 6.84
Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer (2009) 5.02
A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature (2013) 3.46
Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell (2007) 3.44
Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. Genes Dev (2011) 3.05
A prospective study of telomere length and the risk of skin cancer. J Invest Dermatol (2008) 2.75
The ageing immune system: is it ever too old to become young again? Nat Rev Immunol (2009) 2.48
A prospective study of telomere length measured by monochrome multiplex quantitative PCR and risk of non-Hodgkin lymphoma. Clin Cancer Res (2009) 2.48
Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo. J Invest Dermatol (2007) 2.11
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev (2012) 2.06
Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J Clin Invest (2010) 1.98
Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS One (2009) 1.90
Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Rep (2013) 1.74
The CUL7 E3 ubiquitin ligase targets insulin receptor substrate 1 for ubiquitin-dependent degradation. Mol Cell (2008) 1.73
C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Oncogene (2008) 1.70
Main roads to melanoma. J Transl Med (2009) 1.67
Chemokines in tumor progression and metastasis. Oncotarget (2013) 1.64
Implications of cellular senescence in tissue damage response, tumor suppression, and stem cell biology. Cold Spring Harb Symp Quant Biol (2009) 1.64
ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc Natl Acad Sci U S A (2007) 1.61
Shorter telomeres associate with a reduced risk of melanoma development. Cancer Res (2011) 1.49
A prospective study of telomere length measured by monochrome multiplex quantitative PCR and risk of lung cancer. Lung Cancer (2011) 1.47
Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J (2010) 1.47
Genetic variants in telomere-maintaining genes and skin cancer risk. Hum Genet (2010) 1.38
Telomere length in white blood cell DNA and lung cancer: a pooled analysis of three prospective cohorts. Cancer Res (2014) 1.35
The atypical E2F family member E2F7 couples the p53 and RB pathways during cellular senescence. Genes Dev (2012) 1.33
p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci U S A (2008) 1.31
Efficient genetic method for establishing Drosophila cell lines unlocks the potential to create lines of specific genotypes. PLoS Genet (2008) 1.30
Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras. Proc Natl Acad Sci U S A (2010) 1.28
NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene (2012) 1.15
A senescence-like cell-cycle arrest occurs during megakaryocytic maturation: implications for physiological and pathological megakaryocytic proliferation. PLoS Biol (2010) 1.14
Association of leukocyte telomere length with colorectal cancer risk: nested case-control findings from the Shanghai Women's Health Study. Cancer Epidemiol Biomarkers Prev (2012) 1.14
The p16(INK4A) tumor suppressor regulates cellular oxidative stress. Oncogene (2010) 1.12
Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma. J Clin Invest (2013) 1.12
Heat shock protein Hsp72 plays an essential role in Her2-induced mammary tumorigenesis. Oncogene (2011) 1.06
Controversial aspects of oncogene-induced senescence. Cell Cycle (2012) 1.04
Epithelial-mesenchymal transition and senescence: two cancer-related processes are crossing paths. Aging (Albany NY) (2010) 1.03
Colorectal adenoma to carcinoma progression is accompanied by changes in gene expression associated with ageing, chromosomal instability, and fatty acid metabolism. Cell Oncol (Dordr) (2012) 1.02
Atg7 Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma. Cancer Discov (2015) 1.02
Smad3 protein levels are modulated by Ras activity and during the cell cycle to dictate transforming growth factor-beta responses. J Biol Chem (2009) 1.02
A mortalin/HSPA9-mediated switch in tumor-suppressive signaling of Raf/MEK/extracellular signal-regulated kinase. Mol Cell Biol (2013) 1.02
Widespread activation of the DNA damage response in human pancreatic intraepithelial neoplasia. Mod Pathol (2009) 1.02
Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never-smoking women in Asia: a report from the female lung cancer consortium in Asia. Int J Cancer (2014) 1.01
Molecular Network Associated with MITF in Skin Melanoma Development and Progression. J Skin Cancer (2011) 1.01
Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis. J Invest Dermatol (2013) 1.00
Ras-induced senescence and its physiological relevance in cancer. Curr Cancer Drug Targets (2010) 0.99
Melanomagenesis: overcoming the barrier of melanocyte senescence. Cell Cycle (2008) 0.97
The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management. J Am Acad Dermatol (2012) 0.96
Telomere length and risk of melanoma, squamous cell carcinoma, and basal cell carcinoma. Cancer Epidemiol (2013) 0.96
Malignant transformation of non-neoplastic Barrett's epithelial cells through well-defined genetic manipulations. PLoS One (2010) 0.95
PP2A-B56α controls oncogene-induced senescence in normal and tumor human melanocytic cells. Oncogene (2011) 0.95
Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest. Cancer Res (2009) 0.95
Oncogene-induced senescence as a new mechanism of disease: the paradigm of erdheim-chester disease. Front Immunol (2014) 0.95
TERT-CLPTM1L polymorphism rs401681 contributes to cancers risk: evidence from a meta-analysis based on 29 publications. PLoS One (2012) 0.94
Nucleotide metabolism, oncogene-induced senescence and cancer. Cancer Lett (2014) 0.94
Protein kinase Cdelta supports survival of MDA-MB-231 breast cancer cells by suppressing the ERK1/2 pathway. J Biol Chem (2009) 0.93
FISH as an effective diagnostic tool for the management of challenging melanocytic lesions. Diagn Pathol (2011) 0.92
p21WAF1/CIP1 gene transcriptional activation exerts cell growth inhibition and enhances chemosensitivity to cisplatin in lung carcinoma cell. BMC Cancer (2010) 0.91
Growth arrest signaling of the Raf/MEK/ERK pathway in cancer. Front Biol (Beijing) (2014) 0.90
Survivin and escaping in therapy-induced cellular senescence. Int J Cancer (2010) 0.90
The cullin7 E3 ubiquitin ligase: a novel player in growth control. Cell Cycle (2008) 0.90
Anterior pituitary adenomas: inherited syndromes, novel genes and molecular pathways. Expert Rev Endocrinol Metab (2010) 0.90
Environmental factors inducing human cancers. Iran J Public Health (2012) 0.89
Telomerase and the aging process. Exp Gerontol (2007) 0.89
p18Ink4c and p53 Act as tumor suppressors in cyclin D1-driven primitive neuroectodermal tumor. Cancer Res (2009) 0.88
Molecular targeted therapies in metastatic melanoma. Pharmgenomics Pers Med (2013) 0.87
Malignancy without immortality? Cellular immortalization as a possible late event in melanoma progression. Pigment Cell Melanoma Res (2011) 0.87
Cyclin D1 activity regulates autophagy and senescence in the mammary epithelium. Cancer Res (2012) 0.87
Characterization of the p53 response to oncogene-induced senescence. PLoS One (2008) 0.86
Significance of cellular senescence in aging and cancer. Cancer Res Treat (2009) 0.86
Down-Regulated NRSN2 Promotes Cell Proliferation and Survival Through PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma. Dig Dis Sci (2015) 0.85
Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells. Oncogene (2014) 0.85
Cellular senescence as a target in cancer control. J Aging Res (2010) 0.85
Overexpression of the DEC1 protein induces senescence in vitro and is related to better survival in esophageal squamous cell carcinoma. PLoS One (2012) 0.85
Nuclear PRAS40 couples the Akt/mTORC1 signaling axis to the RPL11-HDM2-p53 nucleolar stress response pathway. Oncogene (2014) 0.85
Senescence and life span. Pflugers Arch (2009) 0.84
Genome-wide associations studies for melanoma and nevi. Pigment Cell Melanoma Res (2009) 0.84
Genetic regulation of thymocyte progenitor aging. Semin Immunol (2012) 0.83
Kinetics of the cell biological changes occurring in the progression of DNA damage-induced senescence. Mol Cells (2011) 0.83
Dysregulated ΔNp63α inhibits expression of Ink4a/arf, blocks senescence, and promotes malignant conversion of keratinocytes. PLoS One (2011) 0.83
Sp1 regulates Raf/MEK/ERK-induced p21(CIP1) transcription in TP53-mutated cancer cells. Cell Signal (2015) 0.83
Loss of survivin in the prostate epithelium impedes carcinogenesis in a mouse model of prostate adenocarcinoma. PLoS One (2013) 0.82
Epstein-Barr virus (EBV) Rta-mediated EBV and Kaposi's sarcoma-associated herpesvirus lytic reactivations in 293 cells. PLoS One (2011) 0.82
Pituitary senescence: the evolving role of Pttg. Mol Cell Endocrinol (2010) 0.82
Human skin neural crest progenitor cells are susceptible to BRAF(V600E)-induced transformation. Oncogene (2013) 0.82
A new p53 target gene, RKIP, is essential for DNA damage-induced cellular senescence and suppression of ERK activation. Neoplasia (2013) 0.82
PTTG1 attenuates drug-induced cellular senescence. PLoS One (2011) 0.82
Genetics of melanocytic nevi. Pigment Cell Melanoma Res (2015) 0.81
Expression of coxsackie and adenovirus receptor distinguishes transitional cancer states in therapy-induced cellular senescence. Cell Death Dis (2010) 0.80
Noncanonical roles of the immune system in eliciting oncogene addiction. Curr Opin Immunol (2013) 0.80
Pituitary adenoma growth: a model for cellular senescence and cytokine action. Cell Cycle (2009) 0.80
The Role of STAT3 in Thyroid Cancer. Cancers (Basel) (2014) 0.80
Sulforaphane Increases Cyclin-Dependent Kinase Inhibitor, p21 Protein in Human Oral Carcinoma Cells and Nude Mouse Animal Model to Induce G(2)/M Cell Cycle Arrest. J Clin Biochem Nutr (2009) 0.80
Alterations in leukocyte telomere length in workers occupationally exposed to benzene. Environ Mol Mutagen (2014) 0.78
Disruptive chemicals, senescence and immortality. Carcinogenesis (2015) 0.78
Cellular Senescence is a Common Characteristic Shared by Preneoplasic and Osteo-Arthritic Tissue. Open Rheumatol J (2010) 0.77
Macroautophagy and the oncogene-induced senescence. Front Endocrinol (Lausanne) (2014) 0.76
Metabolic alterations accompanying oncogene-induced senescence. Mol Cell Oncol (2014) 0.76
Upregulation of SOX4 antagonizes cellular senescence in esophageal squamous cell carcinoma. Oncol Lett (2016) 0.76
TSH signaling overcomes B-RafV600E-induced senescence in papillary thyroid carcinogenesis through regulation of DUSP6. Neoplasia (2014) 0.76
Cell cycle-specific association of E2F with the p130 E1A-binding protein. Genes Dev (1993) 3.41
BRAF(E600) in benign and malignant human tumours. Oncogene (2007) 2.45
p53-dependent repression of CDK4 translation in TGF-beta-induced G1 cell-cycle arrest. Genes Dev (1995) 1.50
Zeb1 is required for TrkB-induced epithelial-mesenchymal transition, anoikis resistance and metastasis. Oncogene (2011) 1.25
The neurotrophic receptor TrkB: a drug target in anti-cancer therapy? Cell Mol Life Sci (2006) 1.25
Molecular cloning of a pair of human pepsinogen A genes which differ by a Glu----Lys mutation in the activation peptide. Hum Genet (1987) 0.76